TREACE MEDICAL CONCEPTS, INC. (TMCI): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
TMCI Stock Price Chart Interactive Chart >
TMCI Price/Volume Stats
|Current price||$33.51||52-week high||$37.17|
|Prev. close||$34.79||52-week low||$24.25|
|Day high||$35.09||Avg. volume||305,946|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||1.34B|
TREACE MEDICAL CONCEPTS, INC. (TMCI) Company Bio
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Latest News Stream
|Loading, please wait...|
TMCI Latest Social Stream
View Full TMCI Social Stream
Latest TMCI News From Around the Web
Below are the latest news stories about Treace Medical Concepts Inc that investors may wish to consider to help them evaluate TMCI as an investment opportunity.
Treace Medical Concepts, Inc. (TMCI) Q4 2021 Earnings Conference Call May 25, 2021 16:30 ET Company Participants Vivian Cervantes - Investor Relations John Tree - Chief Executive Officer Mark Hare - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Richard Newletter - SBB Liang, Carolina Drury Near -...
PONTE VEDRA, Fla., May 25, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2021. Recent Highlights: Revenue of $18.7 million, a 66% increase over the same period last yearGross margin of 82.2%, an increase of 340 basis points from the same period last yearCompleted initial public offering with $107.1 million in proceeds, net of underwriting discounts, commissions and offering costsInterim results from ALIGN3D™ clinical study demonstrating positive radiographic and patient-reported outcomes starting at 6 weeks and mai...
NEW YORK, NY / ACCESSWIRE / May 25, 2021 / Treace Medical Concepts Inc (NASDAQ:TMCI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 25, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Treace Medical Concepts ([[TMCI]] -2.0%) posted interim results from the ALIGN3D study, a prospective, multicenter trial designed to evaluate Lapiplasty 3D Bunion Correction for management of symptomatic hallux valgus, a joint deformity.The primary effectiveness endpoint of the trial that involved 173 patients is the radiographic recurrence of hallux valgus at 24...
PONTE VEDRA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 25, 2021. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (833) 730-3977 for domestic callers or (720) 405-2122 for international callers, followed by Conference ID: 1157038. A live and archived webcast of the event will be available on the Company’s investors relations web...
TMCI Price Returns